CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

NCT ID: NCT04734873

Last Updated: 2022-09-21

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-25

Study Completion Date

2021-08-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 3, randomized, placebo controlled, double-blind, multicenter, stratified study of CPI-006 plus standard of care (SOC) versus placebo plus SOC in mild to moderately symptomatic hospitalized Covid-19 patients with the primary objective to compare the proportion of participants alive and respiratory failure free between CPI-006 plus SOC versus placebo plus SOC.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CPI-006 (2 mg/kg) Plus Standard of Care

Participants will receive a single dose of CPI-006 at 2 mg/kg up to a maximum dose of 200 mg intravenously on Day 1 plus standard of care.

Group Type EXPERIMENTAL

CPI-006 2 mg/kg + SOC

Intervention Type DRUG

IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care

CPI-006 (1 mg/kg) Plus Standard of Care

Participants will receive a single dose of CPI-006 at 1 mg/kg up to a maximum dose of 100 mg intravenously on Day 1 plus standard of care.

Group Type EXPERIMENTAL

CPI-006 1 mg/kg + SOC

Intervention Type DRUG

IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care

Placebo Plus Standard of Care

Participants will receive a single dose of placebo intravenously on Day 1 plus standard of care.

Group Type PLACEBO_COMPARATOR

Placebo + SOC

Intervention Type DRUG

IV placebo plus standard of care

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CPI-006 2 mg/kg + SOC

IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care

Intervention Type DRUG

CPI-006 1 mg/kg + SOC

IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care

Intervention Type DRUG

Placebo + SOC

IV placebo plus standard of care

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed positive by polymerase chain reaction (PCR) or antigen test for SARS-CoV-2 with sample collection ≤ 10 days prior to randomization
* Covid-19 illness of any duration of symptoms
* Hospitalized for Covid-19 for ≤ 5 days with mild to moderate Covid-19 symptoms and meets criteria for either Category 4, Category 5, or Category 6 per 8-point ordinal scale
* Adequate organ function
* Participants of child-bearing age must agree to use adequate contraception for 6 weeks after study treatment administration

Exclusion Criteria

* Signs of acute respiratory distress syndrome or respiratory failure necessitating mechanical ventilation at time of screening/randomization or anticipated need for mechanical ventilation
* History of severe chronic respiratory disease and requirement for long-term oxygen therapy
* Uncontrolled active systemic infection or hemodynamic instability requiring admission to an intensive care unit
* Malignant tumor receiving treatment, or other serious systemic diseases affecting life expectancy within 29 days of screening
* Receipt of cancer chemotherapy or immunomodulatory drugs during preceding 2 months (steroids for treatment of Covid-19 are acceptable)
* Convalescent plasma (CCP) or anti-SARS-CoV-2 monoclonal antibodies administered \<24 hours prior to randomization. Must have recovered from any adverse events related to CCP treatment. Received chloroquine or hydroxychloroquine within last 7 days or during the study
* Current participation in other clinical trials including extended access programs
* Active deep vein thrombosis or pulmonary embolism within last 6 months
* Anticipated discharge from hospital or transfer to another hospital which is not a study site within 48 hours of admission
* Active uncontrolled co-morbid disease that may interfere with study conduct or interpretation of findings
* Known to be positive for HIV or positive test for chronic HBV infection or positive test for hepatitis C antibody
* Pregnancy or breast feeding
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Corvus Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

S. Mahabhashyam, MD, MPH

Role: STUDY_CHAIR

Corvus Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sharp Chula Vista Medical Center

Chula Vista, California, United States

Site Status

El Centro Regional Medical Center

El Centro, California, United States

Site Status

Sharp Grossmont Hospital

La Mesa, California, United States

Site Status

Torrance Memorial Medical Center

Torrance, California, United States

Site Status

Mayo Clinic - Jacksonville

Jacksonville, Florida, United States

Site Status

Cambridge Medical Trials

Alexandria, Louisiana, United States

Site Status

MedPharmics

Metairie, Louisiana, United States

Site Status

Holy Cross Hospital

Silver Spring, Maryland, United States

Site Status

Mayo Clinic - Rochester

Rochester, Minnesota, United States

Site Status

Stony Brook University Medical Center

Stony Brook, New York, United States

Site Status

Cape Fear Valley Medical Center

Fayetteville, North Carolina, United States

Site Status

Lehigh Valley Health Network

Allentown, Pennsylvania, United States

Site Status

Temple University Hospital

Philadelphia, Pennsylvania, United States

Site Status

Clinica Zabala

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Clínica Adventista Belgrano

Estomba, Buenos Aires, Argentina

Site Status

Instituto Medico Platense

La Plata, Buenos Aires, Argentina

Site Status

Clinica Independencia

Munro, Buenos Aires, Argentina

Site Status

Instituto Médico Río Cuarto

Río Cuarto, Córdoba Province, Argentina

Site Status

Centro de Investigación Clínica - Clínica Viedma

Viedma, Río Negro Province, Argentina

Site Status

Centro Médico IPAM

Rosario, Santa Fe Province, Argentina

Site Status

Hospital Provincial Del Centenario

Rosario, Santa Fe Province, Argentina

Site Status

Clinica Mayo de U.M.C.B. S.R.L

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status

Hospital de Clínicas Presidente Dr. Nicolás Avellaneda

San Miguel de Tucumán, Tucumán Province, Argentina

Site Status

Fundación Sanatorio Güemes

Buenos Aires, , Argentina

Site Status

Sanatorio Finochietto

Buenos Aires, , Argentina

Site Status

Hospital Rawson

Córdoba, , Argentina

Site Status

Hospital Vera Cruz

Belo Horizonte, Minas Gerais, Brazil

Site Status

Hospital Agamenon Magalhães

Recife, Pernambuco, Brazil

Site Status

Santa Casa de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital Dia do Pulmão

Blumenau, Santa Catarina, Brazil

Site Status

Clínica Supera

Chapecó, Santa Catarina, Brazil

Site Status

Centro Hospitalar Nossa Saúde

Curitiba, , Brazil

Site Status

Universidade Municipal São Caetano do Sul

São Caetano do Sul, , Brazil

Site Status

Conjunto Hospitalar do Mandaqui

São Paulo, , Brazil

Site Status

Hospital Anchieta

São Paulo, , Brazil

Site Status

Hospital de Base Da Faculdade de Medicina de São José Do Rio Preto

São Paulo, , Brazil

Site Status

Hospital E Maternidade Celso Pierro PUCCAMP

São Paulo, , Brazil

Site Status

Universidade Federal Do Espirito Santo - Hospital Universitário Cassiano Antônio de Moraes - HUCAM

Vitória, , Brazil

Site Status

Toronto General Hospital

Toronto, Ontario, Canada

Site Status

Hôpital Maisonneuve-Rosemont

Montreal, Quebec, Canada

Site Status

Hospital Base de Osorno

Concepción, , Chile

Site Status

Clinica Vespucio

La Florida, , Chile

Site Status

Research Network Consulting

Linares, , Chile

Site Status

Clínica Dávila Y Servicios Médicos SA

Santiago, , Chile

Site Status

Rodrigo Botero S.A.S

Medellín, Antioquia, Colombia

Site Status

Fundacion Santa Fe de Bogota

Bogotá, Cundinamarca, Colombia

Site Status

Clínica Universidad De la Sabana

Chía, Cundinamarca, Colombia

Site Status

Fundacion Centro de Excelencia en Enfermedades Cronicas No Transmisibles

Montería, Departamento de Córdoba, Colombia

Site Status

Clínica de la Mujer S.A.S.

Bogotá, , Colombia

Site Status

Hospital Universitario Clinica San Rafael

Bogotá, , Colombia

Site Status

Fundacion Hospitalaria San Vicente de Paul

Medellín, , Colombia

Site Status

Promotora Medica Las Américas S.A- Clínica Las Américas

Medellín, , Colombia

Site Status

Fundación Valle Del Lili

Santiago de Cali, , Colombia

Site Status

Medizinische Hochschule Hannover

Hanover, Lower Saxony, Germany

Site Status

Azienda Ospedaliera Cotugno

Napoli, Campania, Italy

Site Status

ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco

Milan, Lombardy, Italy

Site Status

ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda

Milan, Lombardy, Italy

Site Status

ASST Santi Paolo e Carlo - Azienda Universitaria-Polo Universitario San Paolo

Milan, Lombardy, Italy

Site Status

Ospedale San Raffaele S.r.l.

Milan, Lombardy, Italy

Site Status

ASST di Monza - Azienda Ospedaliera San Gerardo

Monza, Lombardy, Italy

Site Status

Fondazione IRCCS Policlinico San Matteo di Pavia

Pavia, Lombardy, Italy

Site Status

ASST della Valle Olona - Azienda Ospedaliera Ospedale Di Circolo Di Busto Arsizio

Busto Arsizio, , Italy

Site Status

Hospital Civil Fray Antonio Alcalde

Guadalajara, Jalisco, Mexico

Site Status

Hospital Universitario Dr. Jose Eleuterio González

Monterrey, Nuevo León, Mexico

Site Status

Hospital Civil de Culiacán

Culiacán, Sinaloa, Mexico

Site Status

Hospital General de Culiacán

Culiacán, Sinaloa, Mexico

Site Status

Hospital Nacional Sergio E. Bernales

Comas, Lima region, Peru

Site Status

Hospital Chancay y Servicios Basicos de Salud

Huaral, Lima region, Peru

Site Status

Hospital Central Fuerza Aérea del Perú

Miraflores, Lima region, Peru

Site Status

Hospital María Auxiliadora

San Juan de Miraflores, Lima region, Peru

Site Status

Clínica Providencia

San Miguel, Lima region, Peru

Site Status

Clínica San Pablo

Santiago de Surco, Lima region, Peru

Site Status

Hospital Alberto Sabogal Sologuren

Callao, , Peru

Site Status

Hospital Nacional Adolfo Guevara Velasco Essalud

Cusco, , Peru

Site Status

Hospital Militar Central

Lima, , Peru

Site Status

Hospital Nacional Guillermo Almenara Irigoyen

Lima, , Peru

Site Status

Hospital Costa del Sol

Marbella, Málaga, Spain

Site Status

Complejo Hospitalario de Navarra

Pamplona, Navarre, Spain

Site Status

Hospital del Mar

Barcelona, , Spain

Site Status

Hospital General Universitario de Guadalajara

Guadalajara, , Spain

Site Status

Complejo Asistencial Universitario de Salamanca - H. Clinico

Salamanca, , Spain

Site Status

Hospital Universitario A Coruña

Santiago de Compostela, , Spain

Site Status

Municipal Institution City Clinical Hospital #6 of Dnipropetrovsk Regional Council

Dnipro, Dnipropetrovsk Oblast, Ukraine

Site Status

Kharkiv Regional Clinical Infectious Diseases Hospital

Kharkiv, Kharkivs’ka Oblast’, Ukraine

Site Status

Poltava Regional Clinical Infectious Hospital

Poltava, Poltava Oblast, Ukraine

Site Status

Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1

Vinnytsia, Vinnytsia Oblast, Ukraine

Site Status

Municipal enterprise Volyn Regional Clinical Hospital of Volyn Regional Council

Lutsk, Volyn Oblast, Ukraine

Site Status

MNPE City Hospital No. 6 of Zaporizhzhia City Council

Zaporizhzhia, Zaporizhzhia Oblast, Ukraine

Site Status

Municipal Institution City Hospital #7

Zhaporizhzhya, Zaporizhzhia Oblast, Ukraine

Site Status

CNPE City Clinical Hospital #3 of Chernivtsi City Council

Chernivtsi, , Ukraine

Site Status

Municipal Non-profit Enterprise "City Clinical Hospital # 4" of Dnipro City Council

Dnipro, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Brazil Canada Chile Colombia Germany Italy Mexico Peru Spain Ukraine

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CPI-006-003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pyridostigmine in Severe SARS-CoV-2 Infection
NCT04343963 UNKNOWN PHASE2/PHASE3